ALLMedicine™ Acute Lymphoblastic Leukemia Center

Sep 15th, 2021 - Blinatumomab is a BiTE® (bispecific T-cell engager) immuno-oncology therapy, which has demonstrated significant activity in patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (R/R B-ALL); however, a subset of patien...

Sep 15th, 2021 - Bleeding and thrombotic events are an emerging toxicity associated with chimeric antigen receptor (CAR) therapies. To determine their incidence, we retrospectively analyzed consecutive adult patients (n=127) with large B-cell lymphoma (LBCL) or B-...

Sep 14th, 2021 - A wider use of L-asparaginase in the treatment of children with acute lymphoblastic leukemia has improved cure rates during recent decades and hence led to introduction of pediatric-inspired treatment protocols for adolescents and young adults. In...

Sep 14th, 2021 - The standard treatment for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) in Japan is imatinib-based chemotherapy followed by allogeneic hematopoietic stem cell transplantation (HSCT). However, approximately 40%...

Sep 13th, 2021 - Relapsed acute lymphoblastic leukemia.|2021|Chen JL,Vatanatham CC,Tsui E,|

Jan 8th, 2020 - Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy. Advancements in technology that enhance our understanding of the biology of the disease, risk-adapted therapy, and enhanced supportive care have contributed to improved su...

Sep 7th, 2017 - The prognosis for patients with newly diagnosed acute lymphoblastic leukemia (ALL) has improved with the use of more intensive chemotherapy regimens, tyrosine kinase inhibitors, targeted agents, and allogeneic hematopoietic cell transplantation. H...

Jan 3rd, 2012 - Clinical research published since the first evidence-based review on the role of hematopoietic stem cell transplantation (SCT) in the treatment of pediatric acute lymphoblastic leukemia (ALL) is presented and critically evaluated in this update. T...

Sep 10th, 2021 - The investigators will conduct a prospective cohort study of all patients who received CAR T cell infusions in the hematology department from Montpellier University Medical Center. To be eligible for enrollment, patients should have to be 18 years...

Sep 8th, 2021 - About 25% of adult patients with acute lymphoblastic leukemia (ALL) are associated with t (9; 22), positive philadelphia chromosome (Ph+ ALL), in whom BCR/ABL fusion gene can be detected in the bone marrow and peripheral blood. The use of tyrosine...

Sep 8th, 2021 - Primary Objectives (Feasibility Phase) To determine the feasibility of non-invasive collection of continuous physiological data in children with acute lymphoblastic leukemia during outpatient treatment. (Completion Phase) To develop competing seps...

Sep 2nd, 2021 - This is a phase I study of venetoclax in combination with inotuzumab ozogamicin for the treatment of CD22-positive (CD22+) B-cell acute lymphoblastic leukemia (B-ALL) and lymphoma (B-LBL), hereafter referred to as "ALL," in patients with disease r...

Sep 2nd, 2021 - PRIMARY OBJECTIVE: I. To evaluate the overall response rate (complete response [CR] + CR with inadequate count recovery [CRi]) of the regimen within 3 cycles. SECONDARY OBJECTIVES: I. Evaluate other clinical efficacy endpoints (CR rate, minimal re...

Aug 18th, 2021 - Ibrahim Aldoss, MD: Which patients with Philadelphia chromosome-positive [Ph+] acute lymphoblastic leukemia may be safely treated in the community setting versus being referred to tertiary centers? Let’s extend that also to Philadelphia chromosome...

Aug 18th, 2021 - Ibrahim Aldoss, MD: Are your treatment goals different based on age and Ph-negative ALL [acute lymphoblastic leukemia]? And typically, if we're still talking about AYA (adolescent and young adult) versus older adults, or even with the AYA, there's...

Aug 11th, 2021 - Data from the following presentations are discussed: Minimal residual disease at end of induction and consolidation remain important prognostic indicators for newly diagnosed children and young adults with very high-risk (VHR) B-lymphoblastic leu...

Aug 11th, 2021 - Data from the following presentations are discussed: Preliminary results of the GIMEMA LAL2317 sequential chemotherapy-blinatumomab front-line trial for newly diagnosed adult Ph-negative B-lineage ALL patients. (Bassan, EHA 2021 S114) Efficacy: ...

Aug 11th, 2021 - Data from the following presentations are discussed: Combination of ponatinib and blinatumomab in Philadelphia chromosome-positive acute lymphoblastic leukemia: Early results from a phase II study. (Short, ASCO 2021 Abstract 7001) Efficacy: 28 p...